ABL Bio Receives Approval to Amend Phase 1 IND for ABL503 Combination Therapy
Monotherapy Cohorts Targeting New Cancer Types
ABL Bio announced on July 9 that it plans to conduct Phase 1 clinical trials of its bispecific antibody immuno-oncology drug ABL503 (also known as Lazistomig) under an amended Investigational New Drug (IND) application.
ABL503 is a bispecific antibody targeting PD-L1 and 4-1BB, currently being co-developed by ABL Bio and U.S.-based biotechnology company Novabrigde Biosciences. The drug utilizes ABL Bio's proprietary 4-1BB-based bispecific antibody platform, Grabody-T.
Grabody-T is a platform technology designed to overcome the liver toxicity associated with traditional 4-1BB monoclonal antibodies by developing 4-1BB in a bispecific antibody structure that induces activation of immune cells known as T cells. ABL Bio combined the PD-L1 antibody—a key oncology target associated with cancer cells—with Grabody-T to develop ABL503, aiming to overcome resistance and low response rates observed with existing PD-(L)1 inhibitors.
According to the amended Phase 1 IND, ABL Bio and Novabrigde plan to conduct new tumor cohort studies of ABL503 monotherapy in the tumor expansion part of the existing Phase 1 trial at more than eight institutions across Korea and the United States. In addition, they will evaluate the safety and tolerability of both ABL503 monotherapy and the combination therapy of ABL503 with a PD-1 inhibitor through dose escalation and dose expansion phases.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Sanghoon Lee, CEO of ABL Bio, stated, "We expect that the 4-1BB bispecific antibody will demonstrate promising results in solid tumors with high unmet needs when used in combination therapy." He added, "We will accelerate the clinical development of ABL503 to create a new therapeutic agent that overcomes the limitations of current PD-(L)1 inhibitors."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.